Stifel Financial Corp lifted its stake in Cambrex Co. (NYSE:CBM) by 66.6% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 7,629 shares of the biotechnology company’s stock after purchasing an additional 3,049 shares during the period. Stifel Financial Corp’s holdings in Cambrex were worth $420,000 at the end of the most recent quarter.
Several other institutional investors also recently modified their holdings of CBM. YorkBridge Wealth Partners LLC increased its holdings in shares of Cambrex by 5.2% in the second quarter. YorkBridge Wealth Partners LLC now owns 1,971 shares of the biotechnology company’s stock valued at $118,000 after purchasing an additional 97 shares in the last quarter. Riverhead Capital Management LLC increased its holdings in shares of Cambrex by 90.3% in the second quarter. Riverhead Capital Management LLC now owns 2,664 shares of the biotechnology company’s stock valued at $159,000 after purchasing an additional 1,264 shares in the last quarter. Advisor Group Inc. increased its holdings in shares of Cambrex by 29.8% in the second quarter. Advisor Group Inc. now owns 2,681 shares of the biotechnology company’s stock valued at $160,000 after purchasing an additional 615 shares in the last quarter. Trexquant Investment LP acquired a new stake in shares of Cambrex in the third quarter valued at approximately $209,000. Finally, Flinton Capital Management LLC increased its holdings in shares of Cambrex by 90.9% in the second quarter. Flinton Capital Management LLC now owns 3,570 shares of the biotechnology company’s stock valued at $213,000 after purchasing an additional 1,700 shares in the last quarter.
Separately, Craig Hallum reaffirmed a “buy” rating and issued a $60.00 price objective (down from $70.00) on shares of Cambrex in a research note on Tuesday, October 31st. One research analyst has rated the stock with a sell rating, two have issued a hold rating and three have assigned a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $62.33.
Cambrex (NYSE:CBM) last announced its quarterly earnings data on Tuesday, November 7th. The biotechnology company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.08. Cambrex had a net margin of 18.79% and a return on equity of 23.42%. The firm had revenue of $112.60 million for the quarter, compared to analysts’ expectations of $108.44 million. During the same period last year, the firm earned $0.47 earnings per share. The business’s revenue for the quarter was up 13.4% on a year-over-year basis. equities analysts predict that Cambrex Co. will post 2.97 EPS for the current fiscal year.
COPYRIGHT VIOLATION NOTICE: “Stifel Financial Corp Raises Position in Cambrex Co. (CBM)” was reported by Sports Perspectives and is the property of of Sports Perspectives. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international copyright and trademark laws. The correct version of this piece of content can be viewed at https://sportsperspectives.com/2018/01/01/stifel-financial-corp-raises-position-in-cambrex-co-cbm.html.
Cambrex Company Profile
Cambrex Corporation (Cambrex) is a life sciences company. It provides products and services for the development and commercialization of generic therapeutics. It operates through four segments, which are manufacturing facilities that have been aggregated as a single segment. Its manufacturing facilities are owned by the subsidiaries, including Cambrex Charles City, Inc, Cambrex Karlskoga AB and Cambrex Profarmaco Milano S.r.l.
Want to see what other hedge funds are holding CBM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Cambrex Co. (NYSE:CBM).
Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.